East India Pharmaceutical Annual Reports, Balance Sheet and Financials

East India Pharmaceutical Works Limited Balance Sheet (Rs in Lakhs)

East India Pharmaceutical Works Limited Profit & Loss Statement (Rs in Lakhs)

East India Pharmaceutical Works Limited Cash Flow Statement (Rs in Lakhs)

Here is a summary of the Cash Flow Statement for the years 2024 and 2023:

Cash Flow from Operating Activities:

Net Profit / (Loss) before tax & extraordinary items:

For FY 2024, the company reported a net profit of ₹307.81 million, up from ₹243.07 million in FY 2023.

Adjustments:

Depreciation/Amortisation: Increased slightly to ₹258.15 million in FY 2024 from ₹243.57 million in FY 2023, indicating higher non-cash expenses related to asset depreciation.

(Profit) / Loss on sale of Fixed Assets: A profit of ₹8.82 million was realized in FY 2024 compared to a profit of ₹3.11 million in FY 2023.

Interest Received: The interest received decreased to ₹3.22 million in FY 2024 from ₹4.79 million in FY 2023.

Prior Period / Extraordinary Items: ₹146.28 million of extraordinary items were recorded in FY 2024, while no such items were recorded in FY 2023.

Finance Cost: The finance cost increased to ₹546.94 million in FY 2024 from ₹469.31 million in FY 2023, suggesting higher interest expenses or borrowing costs.

Operating Profit before working capital changes: Operating profit increased to ₹1,247.14 million in FY 2024 from ₹948.05 million in FY 2023.

Changes in Working Capital:

Inventories: Inventories increased by ₹287.44 million in FY 2024, whereas they decreased by ₹786.96 million in FY 2023, implying higher stock levels in the current year.

Trade & Other Receivables: The receivables increased by ₹1,738.53 million in FY 2024 compared to ₹1,986.62 million in FY 2023, which negatively impacts cash flow.

Trade & Other Payables: Payables increased by ₹1,133.05 million in FY 2024, compared to ₹158.03 million in FY 2023, positively impacting cash flow.

Cash Generated from Operations: The cash generated from operations improved significantly to ₹354.22 million in FY 2024 from a negative ₹93.58 million in FY 2023.

Direct Tax Paid: The tax outflow was lower in FY 2024 at ₹121.47 million compared to ₹217.36 million in FY 2023.

Net Cash Flow from Operating Activities: As a result, the company had a positive net cash inflow from operating activities of ₹232.75 million in FY 2024, compared to a negative outflow of ₹310.94 million in FY 2023.

Cash Flow from Investing Activities:

Purchase of Fixed Assets: The outflow for fixed assets was ₹129.88 million in FY 2024, lower than ₹191.81 million in FY 2023.

Sale of Fixed Assets: The company generated ₹17.76 million from the sale of assets in FY 2024, slightly less than ₹24.5 million in FY 2023.

Net Cash Flow from Investing Activities: The net cash outflow from investing activities was ₹112.12 million in FY 2024, an improvement from the outflow of ₹167.31 million in FY 2023.

Cash Flow from Financing Activities:

Proceeds from / (Repayment of) Borrowings (Net): The net borrowings amounted to ₹300.35 million in FY 2024, down from ₹933.48 million in FY 2023, indicating reduced reliance on external financing.

Payment of Dividend and Dividend Tax: The outflow for dividends and taxes was ₹46.71 million in FY 2024, down from ₹83.44 million in FY 2023.

Finance Cost: The finance cost remained the same as mentioned earlier at ₹546.94 million in FY 2024 and ₹469.31 million in FY 2023.

Interest Received: Interest received was the same as mentioned earlier at ₹3.22 million in FY 2024 and ₹4.79 million in FY 2023.

Net Cash Flow from Financing Activities: The net cash outflow from financing activities was ₹290.08 million in FY 2024, compared to a positive inflow of ₹385.52 million in FY 2023.

Net Cash Inflow: The overall net cash inflow for FY 2024 was negative at ₹169.45 million, a larger outflow compared to ₹92.73 million in FY 2023.

Cash & Cash Equivalents:

Opening Balance: The opening cash balance was ₹729.19 million for FY 2024, down from ₹821.92 million in FY 2023.

Closing Balance: The closing cash balance decreased to ₹559.74 million in FY 2024 from ₹729.19 million in FY 2023.

Financial Ratios of East India Pharmaceutical Works Limited

Here is a summary of the financial and operational metrics for East India Pharmaceutical Works Limited for the years 2024 and 2023:

Current Ratio (2024: 1.45, 2023: 1.47)

Insight: The current ratio has slightly decreased from 1.47 in 2023 to 1.45 in 2024. This ratio measures the company 's ability to pay off its short-term liabilities with its short-term assets. A ratio above 1 indicates good short-term financial health, but the slight decline suggests a marginal reduction in liquidity.

Debt-Equity Ratio (2024: 0.88, 2023: 0.88)

Insight: The debt-equity ratio remains constant at 0.88, indicating the company’s leverage has not changed. This ratio reflects the proportion of debt and equity used to finance the company 's assets. A stable ratio suggests consistent financial leverage.

Debt Service Coverage Ratio (DSCR) (2024: 2.44, 2023: 2.21)

Insight: The DSCR has improved from 2.21 in 2023 to 2.44 in 2024. This ratio measures the company 's ability to service its debt with its operating income. An increase in DSCR indicates an enhanced ability to meet debt obligations, which is a positive sign of financial stability.

Return on Equity (ROE) (2024: 6.89%, 2023: 3.21%)

Insight: ROE has significantly increased to 6.89% in 2024 from 3.21% in 2023. ROE measures the return generated on shareholders ' equity. The increase suggests that the company is generating more profit from its equity base, indicating improved profitability and efficiency in using shareholders ' funds.

Inventory Turnover Ratio (2024: 56, 2023: 56)

Insight: The inventory turnover ratio remains unchanged at 56. This ratio indicates how many times the company 's inventory is sold and replaced over a period. A consistent ratio suggests stable inventory management and sales performance.

Trade Receivables Turnover Ratio (2024: 179, 2023: 170)

Insight: The trade receivables turnover ratio has increased to 179 in 2024 from 170 in 2023. This ratio measures how quickly the company collects cash from its customers. The improvement indicates faster collection of receivables, which enhances cash flow.

Trade Payables Turnover Ratio (2024: 222, 2023: 226)

Insight: The trade payables turnover ratio has slightly decreased to 222 in 2024 from 226 in 2023. This ratio measures the rate at which the company pays off its suppliers. A slight decline may suggest the company is taking longer to pay its suppliers, which could be a strategy to manage cash flow.

Net Capital Turnover Ratio (2024: 4.59, 2023: 4.63)

Insight: The net capital turnover ratio has decreased slightly from 4.63 in 2023 to 4.59 in 2024. This ratio indicates how efficiently the company is using its working capital to generate sales. A minor decrease suggests a slight reduction in the efficiency of working capital management.

Net Profit Ratio (2024: 1.55%, 2023: 0.72%)

Insight: The net profit ratio has more than doubled from 0.72% in 2023 to 1.55% in 2024. This ratio measures the percentage of profit generated from total revenue. The significant improvement indicates better cost management and higher profitability.

Return on Capital Employed (ROCE) (2024: 9.49%, 2023: 7.19%)

Insight: ROCE has increased from 7.19% in 2023 to 9.49% in 2024. This ratio measures the return generated on the total capital employed in the business. The improvement indicates more efficient use of capital to generate profit, reflecting strong overall financial performance.

Dividend History

East India Pharmaceutical Works Limited Recent Financial Performance

Dividend per Share: The specific dividend per share figure for 2024 and 2023 is Rs. 0.75 and Rs. 0.7 per share. Dividend per share represents the portion of a company 's earnings that is distributed to shareholders in the form of dividends. A higher dividend per share may indicate that the company is sharing more of its profits with shareholders.

Retained Earnings: Retained earnings for 2024 amounted to Rs 336.75 Lakhs, while in 2023, they were Rs. 122.43 Lakhs. Retained earnings represent the portion of a company 's profits that is reinvested in the business rather than distributed as dividends. An increase in retained earnings suggests that the company has retained more of its profits for reinvestment or future growth.

To provide a more comprehensive analysis, it would be necessary to consider additional financial metrics such as revenue, net profit, assets, liabilities, and cash flows. Additionally, an analysis of trends over multiple years and a comparison to industry benchmarks and competitors would help in assessing the company 's financial health and performance.